Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | CRHBP | P24387 | 2/20 | 0.60 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.60 |
| ▸ | PSD | A5PKW4 | 13/20 | 0.58 |
| ▸ | CCR6 | P51684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3751904 | 0.80 | RAD51 (0.74) | RAD51MAPTALDH1A1MCL1PSD | |
| SCHEMBL11642434 | 0.80 | RAD51 (0.73) | RAD51MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL10832522 | 0.70 | RAD51 (0.53) | RAD51MAPTALDH1A1CRHBPCRHR2 | |
| SCHEMBL18439076 | 0.70 | MAP2K1 (0.67) | RAD51MAPTALDH1A1CRHBPCRHR2 | |
| SCHEMBL30452206 | 0.69 | MCL1 (0.56) | RAD51MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL13778057 | 0.68 | PDE10A (0.49) | RAD51MAPTALDH1A1CRHBPCRHR2 | |
| SCHEMBL7711852 | 0.66 | RAD51 (0.62) | RAD51MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL2406895 | 0.66 | XDH (0.63) | MAPTALDH1A1 | |
| SCHEMBL28489642 | 0.65 | MEN1 (0.60) | MAPTALDH1A1MEN1KMT2AMCL1 | |
| SCHEMBL6731942 | 0.65 | MEN1 (0.60) | MAPTALDH1A1MEN1KMT2AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680270-B2 | Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | NQO1, SOD1, MDH2 | RAD51 3582/4885MAPT 1702/4885ALDH1A1 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.